Stock listing
NGNE Stock Price, News, Filings & Events — Neurogene Inc.
Selected listing: NGNE · NASDAQ · USD · US
This page tracks Neurogene Inc.'s NGNE:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NGNE:NASDAQ. NGNE:NASDAQ is the stock-level entry point for investors researching Neurogene Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Neurogene Inc. is a public biotechnology company traded under the ticker NGNE on the American market. The company focuses on developing innovative gene therapies for rare genetic diseases. With a market cap of approximately $695 million, Neurogene is positioned to advance its research and development initiatives in the biotech sector.
- Ticker
- NGNE:NASDAQ
- Asset type
- Stock
- Market cap
- $772.4M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Neurogene Inc. NGNE:NASDAQ stock context
This page tracks Neurogene Inc.'s NGNE:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NGNE:NASDAQ. NGNE:NASDAQ is the stock-level entry point for investors researching Neurogene Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Neurogene Inc. is a public biotechnology company traded under the ticker NGNE on the American market. The company focuses on developing innovative gene therapies for rare genetic diseases. With a market cap of approximately $695 million, Neurogene is positioned to advance its research and development initiatives in the biotech sector.
Latest news from Neurogene Inc.
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
August 11, 2026
Neurogene Inc. Announces Pricing of $125 Million Public Offering
July 1, 2026
Neurogene Inc. Announces Proposed Public Offering
June 30, 2026
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
June 29, 2026
Neurogene Inc. earnings calls
Research Neurogene Inc.
Neurogene Inc. investor report
Review AI stock analysis and investor report context for NGNE:NASDAQ.
Neurogene Inc. company profile
View the public company page for Neurogene Inc. on 6ix.
Neurogene Inc. news
Read company news and market updates connected to Neurogene Inc..
Neurogene Inc. investor events
Find investor webinars, events, and replay context for Neurogene Inc..
Alternate listings
A3EX79:LSX
DE · EUR
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.
A3EX79:LS
DE · EUR
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.
NGNE:BOATS
US · USD
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.
UU8:FWB
DE · EUR
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.
UU8:DUS
DE · EUR
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.
UU8:TRADEGATE
DE · EUR
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.
UU8:SWB
DE · EUR
Alternate listing for Neurogene Inc.; the primary context on this page is NGNE:NASDAQ.